Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a few setbacks

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, will struggle to meet its revenue goal.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) gapped down before the market opened on Wednesday after an insider sold shares in the company. The stock had previously closed at $31.05,

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims & Hers stock plunged more than 50% at one point. Is this once-high-flying healthcare stock a smart buy now?

Shares of Hims & Hers Health ( HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. That jump came as the S&P 500 and Nasdaq Composite showed more modest movements.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug Zepbound and diabetes medicine Mounjaro — and generics of Novo's diabetes drug,